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Abstract
Acquired aplastic anemia (AA) is characterized by partial or total bone marrow 
(BM) destruction resulting in pancytopenia. Most of the acquired AA is the result 
of autoimmune condition the imbalance between T-regulatory cells (Treg), abnor-
mal cytokines production and cytotoxic T cells activation, leading to the hemato-
poietic stem cells (HSCs) death. The first-line treatment is given by HSC transplant, 
but some patients did not respond to the treatment. Therefore, new technologies 
need to treat AA nonresponder patients. Studies are in progress to test the efficacy 
of stem cell-based therapeutic as mesenchymal stem cells (MSCs), which confer 
low immunogenicity and are reliable allogeneic transplants in refractory severe AA 
cases. Furthermore, MSCs comprise the BM stromal niche and have an important 
role in supporting hematopoiesis by secreting regulatory cytokines, providing 
stimulus to natural BM microenvironment. In addition, MSCs have immunomodu-
latory property and are candidates for efficient supporting AA therapy.
Keywords: allogeneic transplant, mesenchymal stem cell,  
immune-mediated aplastic anemia, paracrine effects, immunomodulation
1. Introduction
Aplastic anemia (AA) is a rare disease, caused by bone marrow (BM) aggression 
resulting in hypo or aplastic BM with precocious fat replacement and consequently 
to peripheral blood pancytopenia [1, 2]. The autoimmunity process in AA occurs 
due to the activation of the oligoclonal cytotoxic T cells that will lead the hema-
topoietic cells to apoptosis. Its triggering occurs by the imbalance between CD8 
+, CD4 +, T-Helper (Th), Th type 1 (Th1), Th type 2 (Th2), Th17 type (Th17), 
Natural Killer (NK) and T-regulatory cells (Treg). Besides, there is also an abnormal 
production of proinflammatory cytokines, such as tumor necrosis factor-alpha 
(TNF-α), interferon-gamma (IFN-γ) and transformed growth factor (TGF) [3–7].
For severe cases, immunosuppressive therapy is accepted as the first-line treat-
ment option and the allogeneic transplantation of BM and hematopoietic stem cells 
(HSCs). However, 30–40% of patients with severe aplastic anemia (SAA) remain 
pancytopenia following the treatment. The transplant option still has a restricted 
number of compatibility between suitable donors. Additionally, patients aged 
>50 years are not eligible for transplant [8].
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A new viable alternative for the treatment of AA has been sought and the use 
of mesenchymal stem (MSCs) therapy may be a promising therapeutic candidate 
mainly because of their hypoimmunogenicity and the lack of rejection after trans-
plants and immunomodulatory effects, which may promote decreasing the symp-
toms of the disease [9, 10]. These benefits are attributed to the paracrine effects, 
above all by its ability to regulate the immune system [11].
Actually, is known that MSCs have wide therapeutically potential attributed 
by paracrine effects and the past decades have seen explosion research directed to 
understand better these MSCs mechanism and function [12]. One of the main and 
most important features of MSCs is the low expression of human leukocyte antigen 
(HLA) class I, with no expression of HLA class II. This feature allows the cell to 
be characterized as hypoimmunogenic, since it does not stimulate the patient’s 
immune system and can be used safely in transplants [13]. More recently, the stud-
ies showed that the main cause of AA is autoimmunity. Through the secretion of 
bioactive molecules, MSCs have the capacity of regulating immune responses. The 
mechanism of MSCs may decrease secretion of proinflammatory cytokines such as 
transforming growth factor (TGF), IFN-γ TNF-α, interleukin (IL)-17 and increase 
secretion of many soluble mediators, including anti-inflammatory cytokines stimu-
lation that inhibit antigen-presenting cells (APCs) functions, which are capable to 
decrease proliferation of dendritic cells (DCs) and regulate macrophage activity by 
polarizing proinflammatory phenotype (M1) to anti-inflammatory phenotype (M2) 
[14, 15]. Therefore, the decrease of B cells proliferation and antibodies production 
and adjustment of T cells activities as well as inhibit the proliferation of cytotoxic T 
cells and stimulate Treg activity [16].
MSCs therapy has gained space due to its vast therapeutic potentials such as 
immunomodulation mechanisms and main safety as bioproduct. Thus, this chapter 
will discuss the challenges of allogeneic MSCs as an alternative for an efficient 
therapeutic in AA immune-mediated treatment.
2. Aplastic anemia: general features
AA is a disorder characterized by BM hypocellularity, and peripheral blood 
pancytopenia due to a deficit of HSCs. It affects mostly children, young adults, and 
adults, over 60 years of age [17]. This condition can be similar to other hematologic 
disorders, however, in most cases, the AA is caused by reduced HSCs function, an 
increase in HSCs apoptosis level, consequently, the decreased of HSCs and hemato-
poietic progenitors and lastly, microenvironment fat replacement [18, 19].
Following the patient diagnosis, AA can be considered as moderate or severe. 
The patients with pancytopenia may present symptoms of anemia purpura or 
skin hemorrhage, and in most of the cases there is an infection association, that 
may worsen the symptoms [20]. Three main criteria are used for the diagnostic: 
neutrophil count lower than 0.5 × 109 cells/L, reticulocyte count lower than 1% and 
platelet count lower than 20 × 109 cells/L [21]. To confirm acquired AA, the clinical 
case must be differentiated from other hematological diseases, as well as from the 
signs of malignant cell transformation or myelodysplasia [22].
Normally the first AA etiology is uncertain and for this reason, the disorder is 
considered heterogeneous in origin and characterized as idiopathic [23]. AA is asso-
ciated with exposures to chemical agents (pesticides and benzene), cytotoxic drugs 
(antineoplastics, antibiotics, non-steroidal anti-inflammatory drugs), active viral 
infections exposure (Epstein Barr, hepatitis virus, human immunodeficiency virus 
parvovirus) and radiation exposure [18, 24, 25]. However, these causes considered 
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secondary etiologies, since the studies are directed to the primary etiology of AA 
to autoimmunity [26, 27]. AA pathogenesis involves an immunity dysfunction, 
initially provoked by the activated T cells [23], which leads to an abnormal hemato-
poietic microenvironment, destruction of hematopoietic stem/progenitor cell and 
differentiation deficiency. These findings suggest that the immune system plays an 
important role in the pathogenesis of AA.
2.1 AA pathophysiology
Currently, the studies of AA etiology are focused on the immune mechanism of 
hematopoietic cells destruction. Many researchers [28, 29–31] have demonstrated 
that the dysfunction of T cells might be a key factor in recent characterization as 
an autoimmune disease [28]. Most of the acquired AA is the result of an immune-
mediated process as an imbalance between CD8+ and CD4+ T cells, including Th1, 
Th2, Treg and Th17 cells, NK, and natural killer T cells (NK T) that leads to apopto-
sis of BM cells triggered by cytotoxic T cells activation [6, 17].
The abnormal immunoregulatory cell functions observed in AA can be attribut-
able to abnormal antigen stimulation and some inappropriate T cells activation 
[28]. Studies demonstrated that patients with AA have a significantly increased 
proportion of Th1 cells, and showed a reduced fraction of natural killer T cells and 
regulatory T cells, together with an increased level of TNF-α, a consequent eleva-
tion of IL-6, IL-8, and IL17 productions [18]. Additionally, there is also an abnormal 
production of proinflammatory cytokines including IFN-γ and TGF [4, 5, 28, 32]. 
The new T cells subset was characterized as Th17 and currently is known that both 
Th17 cells and the cytokine IL-17, which is secreted by Th17 cells, also is in an asso-
ciation with AA pathogenesis [31]. Studies showed that AA patients who presented 
an increase in the frequency of Th17 cells had a positive correlation with an increase 
in the IFN- γ and IL-17 expression. Autoimmunity promotes inflammatory Th17 
immune responses that contributed to disease pathophysiology [29].
Otherwise, AA is attributed to inappropriate antigen stimulation and abnormal 
APCs activation [28], resulting in the priming of T cells specific for hematopoietic 
cells [33, 34]. APCs exhibit a significant increase in the expression of major histocom-
patibility class 2 (MHCII), increasing the recognition of CD4+ T cells. In AA, T cells 
are also stimulated by unknown antigens or abnormal APC activation as DCs and 
macrophages, which trigger a series of immune responses. Studies have shown that 
immunoregulatory cell dysfunction leads to a corresponding immune tolerance disor-
der and renders the body unable to recognize autologous hematopoietic cells [28].
Although the definitive mechanism has not been identified, some genetic factors 
are the targets of ongoing research, such as the molecular basis of the aberrant 
immune response and hematopoietic cell deficiency, telomere repair gene muta-
tions in the target cells and unregulated T cell activation pathways and cytokine 
genes polymorphisms [9, 26, 28]. These changes in the nucleotide sequence and 
gene regulation are associated with an increased immune response and suggest a 
genetic basis for aberrant T cells activation in BM failure [35].
2.2 AA treatment
The treatment depends on the severity of the disease, once for moderate 
cases are based on red blood cell (RBC) transfusions, on platelet transfusions to 
prevent bleeding, and on supportive care in association with antibiotic aiming to 
reestablish blood cell volume and prevent secondary infections [17]. However, the 
pancytopenia of many moderate cases may progress to severe [21]. For severe cases, 
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immunosuppressive therapy is accepted as a first-line treatment option. However, 
30–40% of patients with SAA remain pancytopenia following the treatment. 
Patients with SAA, which are refractory or have a relapse after immunosuppres-
sive treatment, may undergo allogeneic hematopoietic stem cells transplantation 
(HSCT). However, about one-third of patients do not have a suitable donor for 
HSCT. Additionally, patients aged >50 years are not eligible for transplant [8].
Furthermore, the immunosuppressive drug treatment has several side effects 
on patients. On the other hand, the patients often do not respond adequately to 
the therapies and are not suitable for life treatment (refractory patients) [24]. 
Therefore, immunosuppressive drugs are considered supporting AA treatment, 
once it does not promote the cure [20].
2.3 Allogeneic transplantation and alternative methods for AA treatment
Generally, patients are treated with allogeneic HSCs or whole BM transplanta-
tions, which replace since HSCs, hematopoietic precursors, until differentiated 
bloodstream cells and immune system cells. However, in all types of transplants, 
the treatment involves a combination of immunosuppressive agents or radiation 
therapy to prevent and to eliminate residual host BM [24]. The transplantation 
success varies according to risk factors, such as age and mainly histocompat-
ibility allogeneic HLA-matched sibling donors, which are rare for the majority of 
patients. Despite being well established for many years, the transplanted patients 
can trigger late complications, such as the development of graft versus host disease 
(GVHD) and infections, especially in patients who have received hematopoietic 
grafts from HLA antigen matched donor [36, 37]. Studies show that the incidence 
of GVHD after unrelated donor transplantation can achieve ∼14%, and overall 
survival index was 57% for all 8 HLA-loci matched transplants and 39% for 1-loci 
mismatched transplant [38]. Thus, for BM and HSCT, the immediate challenge is 
the extension of stem cell therapies to all patients, regardless of age, with a histo-
compatible sibling [24].
Since then a new viable alternative for the treatment of AA has been sought 
and the use of MSCs transplantation becomes of choice. The MSCs therapy may 
be a promising therapeutic candidate mainly because of their hypoimmunoge-
nicity, the lack of rejection after transplants and immunomodulatory effects, 
which may promote decreasing the symptoms of the disease [39]. These benefits 
are attributed to MSCs paracrine effects, above all to their ability to regulate the 
immune system. MSCs may help for AA treatment, especially for autoimmune 
type [11].
3. Mesenchymal stem cell: general features
MSCs are multipotent progenitors, which were first isolated from an adult 
organism by Friedenstein and colleagues in 1968, and described years later by 
Caplan and colleagues [40, 41]. These cells include firstly an inherent autocrine 
effect, as self-renewal and differentiation potential for a variety of cell types, as 
main adipocytes, osteoclasts, and chondrocytes [42], depending on the surround-
ing microenvironment conditions [43]. Currently, such cells have shown to be 
isolated from many postnatal and adult tissues, such as adipose tissue, umbilical 
cord, placenta, dental pulp, and others [44, 45].
Initially, the mechanism therapeutic potential of the MSCs was based only 
on the potential for regeneration through cellular self-renewal and its plasticity. 
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Further studies have shown low engraft of MSCs in injured areas that questioned 
the hypothesis that MSCs repair tissue damage by replacing cell loss with newly 
differentiated cells [46, 47].
3.1 MSC: paracrine effects
It is known that MSCs have wide therapeutically potential attributed to paracrine 
effects and the past decades explosion research was directed to understand better 
these MSCs mechanism and function [12]. Although the therapeutic mechanisms of 
MSCs are not yet well characterized, it is possible to say that their paracrine effects 
consist in the secretion of bioactive molecules such as a variety of cytokines and 
growth factors as like anti-inflammatory, anti-apoptotic and angiogenic [46–51].
MSCs can to migrate to the lesion site through signals from specific chemokines. 
This process called homing consists of the steps of activating adhesion molecules, 
rolling to the endothelium, adhesion, and migration to the tissue that is the source 
of chemokine inflammation production [52, 53]. The current hypothesis is that 
paracrine factors secreted by MSCs promote protective microenvironment and 
repair by local tissue-resident progenitor populations, favoring the hypothesis of 
detecting favorable effects even in the absence of the cells at lesion sites [54].
3.2 MSC: immunogenic effect and safety for transplantation
One of the main and most important features of MSC is the low expression of 
HLA class I, with no expression of HLA class II. Also, MSCs do not appear to express 
the co-stimulatory molecules CD80 or CD86 required for effector T cell induction 
[55]. The absence of co-stimulatory molecules implies that any residual engagement 
of the T cell receptor on Th cells would result in absence of the normal immune 
response to a particular antigen and contribute to tolerance rather than allogeneic 
responses. This feature allows the cell to be characterized as hypoimmunogenic, 
since it does not stimulate the patient’s immune system and can be used safely in 
transplants [113. As well, MSCs have properties attributed to immune functions, 
indicating their ability to immunomodulatory activity. Studies indicated that MSCs 
can regulate immune responses during chronic inflammation through the innate and 
adaptive immune system, regulating the recruitment and their function [56, 57].
3.3 MSC: immunomodulatory potential
The paracrine effects of MSCs may have great importance in the treatment of 
autoimmune diseases. Through the secretion of bioactive molecules, MSCs have the 
capacity of regulating immune responses. These cells can regulate adaptive immune 
responses through multiple redundant pathways, interacting with various immune 
cells and secreting soluble mediators such as IL-6, IL-10, prostaglandin E2 (PGE2), 
nitric oxide (NO), transforming growth factor-β1 (TGF-β1), and hepatocyte 
growth factor (HGF), indoleamine-pyrrole 2, 3-dioxygenase (IDO) [58, 59]. They 
can regulate APCs activity, decreasing maturation and proliferation of DCs [14]. 
MSC also may regulate macrophage activity by polarizing its pro-inflammatory 
phenotype (M1) to its anti-inflammatory phenotype (M2) [15]. Therefore, suppress 
T cell proliferation and activation and regulate the differentiation of Th cells and 
act on the humoral response by inhibiting of B cell activation and antibody produc-
tion [60]. MSCs may also reduce pro-inflammatory cytokines proliferation, such 
TNF-α, which has an important role of the pathogenesis of autoimmune diseases 
and chronic inflammation (Figure 1) [14, 16, 61].
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4. MSC mechanism in AA treatment
The first paracrine effect, showed for MSCs, was the capacity to support HSCs 
growth in vitro. Afterward, adipose tissue (AT) – derived MSCs also supported HSCs 
growth in vitro [62, 63]. Therefore, the most successful clinical application of  
MSCs is involved in the hematological disease.
At BM microenvironment, MSCs niche supports hematopoietic cells and 
produce factors recruiting HSCs and supporting hematopoiesis [64]. This mecha-
nism occurs through chemokine secretion of C-X-C motif chemokine ligand 12 
(CXCL12), which acts on the homing regulation of HSCs, regulating the stages of 
adhesion, expansion and migration [65, 66]. The secretion of other factors is also 
important in the proliferation of HSCs mechanisms such as Flt-3 ligand (FLT3LG) 
[67], thrombopoietin (TPO) [[68] and IL-6 [17]. That despite being a proinflam-
matory cytokine in general, when IL-6 is secreted in BM microenvironment, is 
capable to stimulate hematopoiesis [69, 70].
More recently, the studies showed that the main cause of AA is autoimmunity. 
This process occurs in the result of an imbalance between CD8 + and CD4 + T 
cells, including Th1, Th2, Th17, NK, leading to the death of hematopoietic cells 
and their precursors [28]. Many studies have hypothesized that the onset of the 
immune imbalance in AA begins by stimulating APCs through an unknown antigen 
resulting in the T cells activation [71]. Another important mechanism of MSCs is 
the immunomodulation mechanism. MSCs can act directly on AA imbalance by T 
cells suppression, inhibiting activation and proliferation of T cells [72]. MSCs also 
inhibit the secretion of two important cytokines present in the pathology of AA, the 
Figure 1. 
Benefits of MSCs paracrine effect (immunomodulatory) on immune cells imbalance. MSCs secrete many 
soluble mediators, including anti-inflammatory cytokines stimulation that regulates APCs functions capable 
to decrease proliferation of DCs and regulate macrophage activity by polarizing proinflammatory phenotype 
(M1) to anti-inflammatory phenotype (M2). Therefore, they are responsible for humoral response regulation 
by the decrease of B cells proliferation and antibodies production. The APCs are also capable to regulate 
the T cell activities as well as inhibit cytotoxic T cell proliferation and upregulation and increase of Treg 
cells. MSCs may also promote the decrease of proinflammatory cytokines secretion. And act on the homing 
regulation of HSCs mechanism on stages of adhesion, expansion, and migration through chemokine and 
other factors secretion.
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INF-γ and TNF-α and stimulate the proliferation of Treg, promoting the production 
of the anti-inflammatory cytokine IL-10 Table 1 [73, 74]. In addition, some studies 
also show that MSCs also acts through its anti-apoptotic effects [75].
5. Biodistribution and engraftment of allogeneic MSC in BM
In the last years, several studies have been exploring intravenous administrations 
(IV) due to being safe and do not present morbidity risk for patients. However, still 
lack the data about the biodistribution mechanism of MSCs and about how these 
cells engraftment on the target organ, which is essential for the success of clinical 
studies. It is known that the biodistribution is influenced in vivo and in vitro condi-
tions. Stromal cell-derived factor 1 (SDF-1) (also known as CXCL12) is upregulated 
at sites of injury and acts as a chemoattractant to recruit circulating or residing 
MSCs expressing its cognate receptor CXC chemokine receptor 4 (CXCR4). It has 
been demonstrated that the CXCR4-SDF-1 axis is critical for BM homing [76]. 
Diverse studies demonstrate that some in vitro conditions may influence the expres-
sion of adhesion molecules [77, 78]. For instance, long expansion periods [79] and 
cells culturing at high density may reduce CXCR4 cell expression; the cells cultured 
at higher confluence secrete more metalloproteinase inhibitor 3, which decreases 
migration of MSCs when compared to those cultured at the low confluence [80]. 
Hypoxia condition may increase CXCR4 expression; on the other hand, hypoxia 
may decrease matrix metalloproteinase-2 secretion and an increase in membrane-
type 1 matrix metalloproteinase [81].
In vivo engraftment is influenced by interactions of MSCs with different types 
of immune cells that depend on their ability to respond to signals from the immune 
AA disorders x MSC benefits
Aberrant secretion of pro-inflammatory 
cytokines ↑IFN-γ ↑TNF-α ↑IL-17 ↑IL-2;
Immunomodulatory effect: Decreased secretion of 
proinflammatory cytokines, ↓IFN-γ ↓TNF-α ↓IL-17 ↓IL-2;
Imbalance between CD8+ and CD4+
T cells; ↑ Cytotoxic T cell ↓Treg
Regulation of T cell activity and Treg cell proliferation
↓ Cytotoxic T cell ↑Treg
Apoptosis of HSC and progenitor cells
↑ Apoptosis
Protect BM by antiapoptotic properties
↓ Apoptosis
BM hypoplasia Recovery of BM
↑ Hematopoiesis improvements
↑ CXCL12 ↑FLT3LG ↑TPO ↑IL-6
Abnormal APC activation
↑ DCs ↑ Macrophage
Regulate APCs functions
↓ DCs maturation and proliferation and
↓ Macrophages M1 activation







Irregular activity of NK cells
↑ Cytotoxicity of NK cells
↓ Cytotoxicity of NK cells
MSC can decrease secretion of pro-inflammatory cytokines such as TGF, IFN-γ TNF-α, IL-17, regulate T cell activity, 
inhibit proliferation of cytotoxic T cells and stimulate Treg activity. MSC has anti-apoptotic properties, protects 
BM environment and recovery BM through cytoprotective effect and stimulates macrophages M2 activation and 
hematopoiesis improvements. MSCs may also regulate APCs functions, humoral response, and cytotoxicity of NK cells.
Table 1. 
Table shows disorders characterized in AA and the mechanism of action of MSCs in AA pathology.
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system. On the other hands, the MSCs biodistribution and homing depend on 
the host niche. Interesting the MSCs migration and homing to target tissue can be 
influenced positively by irradiation. It has been demonstrated an increased absolute 
number of human MSCs in the brain, heart, bone marrow, and muscles after total 
body irradiation and MSCs IV administrations in mice, when compared to the 
untreated control [82].
Some animal studies evidence that MSCs can engraftment in BM after systemic 
administration [83]. Studies in patients showed MSCs engraftment into BM 30 days 
after the second MSCs IV administration. Although, after MSCs infusion was 
observed no recovery of hematopoietic tissue, interstitial hemorrhage, edema, and all 
adipocytic necrosis disappeared in BM [84]. Other studies indicate the engraftment 
due to myeloid and plated recovery after HSCs and MSCs transplantation [85, 86].
6. MSC use in clinical studies
6.1 Clinical potential and market of MSC in hematopoietic disorders
MSCs have been implicated in immunomodulatory therapy, in particular, in 
GVHD treatment and as an adjunct to hematopoietic stem cell transplantation 
(HSCT) to help enhance engraftment [87, 88]. The first major clinical trial of MSCs 
(Prochymal) was for the treatment of steroid-refractory of GVHD (NCT00366145) 
[89, 90]. The primary endpoint of the study was complete remission at day 28 
after allogeneic BM-MSCs infusion but was not significantly increased compared 
to placebo [89, 91]. In 2012, MSCs have bens conditional approval to treat children 
GVHD in Canada, based on subset analysis that suggested children with GVHD 
were responsive to MSCs [89, 92, 93]. Many new studies have been developed in 
recent years; however, a few of them have attempted to look at biological correlates 
of response to therapy. Isolated studies reported serum biomarkers of GVHD 
severity including IL-2, tumor necrosis factor receptor 1 (TNFR1), regenerating 
islet-derived protein 3 alpha (Reg3a), and levels of inflammatory cytokines, which 
not clearly correlate with the response in humans. More studies are needed to obtain 
correlative research data [94, 95]. This outcome results in the first Food and Drug 
Administration (FDA) approved MSCs product in the United States [96, 97].
6.2  Clinical studies with MSC in combination to HSCT transplantation for  
treat AA
Cotransplantation of HSCs with (umbilical cord) UC-MSCs has been performed 
to study whether the last will be able to support hematopoiesis, enhance the 
engraftment of HSCs, and reduce the incidence of GVHD following HSCT  
[98–100]. These studies include adult and children in AA patients [101, 102]. Stem 
cells application was mainly intravenous. In some of the studies multiple (five) 
infusions were used. All clinical protocols have been developed in the presence of 
traditional immunosuppressive protocol to prevent GVHD manifestation [98–102].
One pioneer study, where the conditioning of patients was myeloablative or 
reduced, followed BM-MSCs treatment together with allogeneic HSCT. This study 
showed that co-transplantation of MSCs resulted in fast engraftment of absolute 
neutrophil count and platelets and 100% donor chimerism [87]. In turn, Yamei and 
co-workers (2014) demonstrate prolonged survival (follow up of 78 months) in 80.9% 
patients after cotransplantation of the culture-expanded third party donor-derived 
UC-MSCs in 21 young people with SAA undergoing haplo-HSCT [103]. Even so, the 
patients did not show infusion toxicity. This study showed that MSCs support in vivo 
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normal hematopoiesis and display potent immunosuppressive effects. The other 
metacentric study shows that cotransplantation of BM-MSCs and haplo-HSCT could 
reduce the risk of graft failure and severe GVHD in SAA [104]. Similar data were 
obtained in a study that used cotransplantation of haploidentical HSCs and BM-MSCs 
into children with SAA without an HLA-identical sibling donor. It was shown that such 
cotransplantation seems to be safe and may improve survival rates and reduce the risk 
of graft failure [105]. Another multicenter study, which explored cotransplantation 
of BM-MSCs with allo-HSCT, reported that such treatment could ameliorate clinical 
outcomes of a GVHD, viremia, and survival in allo-HSCT for AA patients [106].
6.3 Clinical studies with MSC for treat AA
Nowadays there a few clinical studies using only MSCs single to treat AA. All 
studies used MSCs isolated from BM s and adult patients with severe or non-severe 
AA and refractory. The via of MSCs administration used was IV and the number of 
administrations was 2 until 5 depending on study in combination with conventional 
immunosuppressive therapy.
The study development by Pang et al. showed, six of 18 patients (33.3%) achieved 
a complete response or a partial response to MSCs treatment [107]. In six patients, 
two achieved a complete response including recovery of three hematopoietic cell lines 
after MSCs therapy. Similar results was achieved by Cle et al. 2015 using MSCs being 
22% of all patients (18 patients) presents hematologic response at 6 months after 
MSCs transplantation [108]. One clinical trial phase II conducted in China evaluated 
the MSC overall response rate and safety using a significant number of refractory 
AA younger patients (n = 72). The study performed full quality control of BM-MSCs 
production, which includes counts, viability, morphology, endotoxin, aseptic culture, 
immunophenotype. It was the first clinical study that showed significant results in 
BM functional recovery. The rate response of patients was 28.4% being that 6.8% 
complete response and 21.6% partial response after MSCs transplantation. Among 
patients with hematologic response, ten patients had normalization of cellularity BM 
followed for more than 1 year MSCs transplantation. Seven patients got adverse events 
such as fever and headaches. No other adverse events were observed in the study. At 
the follow-up endpoint, nine patients died. One patient with RAEB-II died of disease 
progression, two patients died of intracranial hemorrhages, and six patients died of 
serious infection [107]. In other two studies were reported adverse events such as, 
fever, hypoxemia, mild dyspnea and diarrhea during MSCs administration or some 
hours after MSCs injection, this phenomenon occurs in 2 of 16 patients [107] and 7 of 
the 18 patients [108]. None major adverse effects were reported in all studies during 
months of follow-up of each respective study. Fuillard et al., 2003 reported one death 
due to fungal infection and Cle et al. 2015 four patients died in consequence result of 
heart failure and bacterial or invasive fungal infections and none of the deaths in both 
studies were directly attributable to MSCs infusions [84, 108].
These preliminary studies support the concept that MSCs replacement can 
improve BM stroma and may alleviate symptoms severe and non-severe AA 
patients. However, larger studies with a significant number of patients are needed to 
evaluate the utility of MSCs further.
7. Conclusion and future perspectives
The progress in dissecting the underlying and complex pathophysiology of AA 
has been gain space over the past years in the hematology research community [26]. 
In addition to that, the need for an optimal alternative of a targeted treatment for 
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this disorder. It is too soon to place the conventional AA treatment methods, but 
MSCs have gained space for demonstrating positive results in several AA clinical 
studies and other hematological diseases. The hypoimmunogenicity advantages, 
ensuring the absence of rejection in patients due to no expression of MHC class II, 
prevention and treatment of GVHD traditional transplants, and mainly immuno-
modulatory action presented [109]. Essential in the environment imbalance pro-
voked by own immune system in people committed by the AA disorder. The MSCs 
are able in a modulating way to relieve the BM self-attack [110].
Contemporary, personalized therapies are famous in the whole scientific world. 
The MSCs may fit into this class due to their paracrine effects. These cells can assist 
in diverse situations such as: migration, injury recovery, stimulates cells renewal, 
death cell prevention, anti-inflammatory and modulation of the immune system to 
control the autoimmune environment [111]. Thus, MSCs have the heterogeneous 
capacity in varied therapies field. And the patient may have alternative use accord-
ing to their needs.
In that event, the current way is providing the MSCs safety and acceptance by 
regulatory agencies as new biological product [112], which has already been proven 
to be more efficient than synthetic industries products [113]. And finally, imple-
ment the MSCs as ideal allogeneic transplant model, even for adequacy periods used 
as support for other established therapies.
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